
BSX's upcoming launches, from SEISMIQ 4CE to FARAFLEX, are likely to provide new growth opportunities across key businesses.
Boston Scientific Corporation, doing business as Boston Scientific, is a manufacturer of medical devices used in interventional medical specialties, including interventional radiology, interventional cardiology, peripheral interventions, neuromodulation, neurovascular intervention, electrophysiology, cardiac surgery, vascular surgery, endoscopy, oncology, urology and gynecology.
| Revenue (TTM) | $21.00B |
| Gross Profit (TTM) | $14.53B |
| EBITDA | $5.71B |
| Operating Margin | 22.90% |
| Return on Equity | 15.30% |
| Return on Assets | 6.19% |
| Revenue/Share (TTM) | $14.19 |
| Book Value | $17.23 |
| Price-to-Book | 2.59 |
| Price-to-Sales (TTM) | 3.03 |
| EV/Revenue | 3.655 |
| EV/EBITDA | 13.62 |
| Quarterly Earnings Growth (YoY) | 15.10% |
| Quarterly Revenue Growth (YoY) | 7.50% |
| Shares Outstanding | $1.45B |
| Float | $1.44B |
| % Insiders | 0.25% |
| % Institutions | 94.73% |
Volatility is currently contracting

BSX's upcoming launches, from SEISMIQ 4CE to FARAFLEX, are likely to provide new growth opportunities across key businesses.

AGCO, AEG and BSX have been added to the Zacks Rank #5 (Strong Sell) List on September 21st, 2026.

Boston Scientific faces near-term pressure in electrophysiology, while Medtronic gains share and sees stronger momentum across key franchises.

AGCO, BSX and BBWI have been added to the Zacks Rank #5 (Strong Sell) List on September 16th, 2026.

Boston Scientific is upgraded to 'Strong Buy' as market overreaction creates an attractive entry point for long-term investors. BSX trades at a forward P/E of 13.1, well below its historical average, despite robust profitability and solid Q2 2026 results. Growth headwinds from WATCHMAN and electrophysiology are offset by strong Interventional Cardiology and Vascular Therapies momentum.

BSX's deal-making push expands its reach into high-growth markets, with Penumbra adding a major thrombectomy opportunity.

Boston Scientific's cyberattack will hurt third-quarter results, but manufacturing and shipping recovered quickly enough that much of the missing revenue should be delayed rather than lost. I am more concerned about WATCHMAN and U.S. electrophysiology, which had already slowed before the attack, and the additional debt coming with Penumbra. BSX shares now trade near 13 times the company's withdrawn earnings forecast. I estimate fair value at $55, leaving enough room for a Buy without assuming that growth immediately returns.

Investors often turn to recommendations made by Wall Street analysts before making a Buy, Sell, or Hold decision about a stock. While media reports about rating changes by these brokerage-firm employed (or sell-side) analysts often affect a stock's price, do they really matter?

Boston Scientific Corporation (BSX) Presents at Wells Fargo 21st Annual Healthcare Conference Transcript

The company said products are moving through its distribution network at or above normal levels as the Marlborough, Mass., company works to fulfill customer orders, reduce backlogs and accelerate the delivery of products.
Tiblio connects your broker and runs your put-and-call-writing strategy for you — on BSX and any ticker you trade — then tracks every position and per-strategy win rate.